Monitoring of Artemisinin Combination Therapy in Igombe ...756196/FULLTEXT01.pdfMonitoring of...
Transcript of Monitoring of Artemisinin Combination Therapy in Igombe ...756196/FULLTEXT01.pdfMonitoring of...
Monitoring of Artemisinin Combination
Therapy in Igombe, Tanzania.
WRITTEN REPORT
Medicine program, degree project (30 hp)
By Johanna Andersson Supervisor: Göte Swedberg Local supervisors in Tanzania: Erasmus Kamugisha & Karol Maro
1
Table of Contents
Acknowledgements ......................................................................................................................... 2
1 Abstract ........................................................................................................................................ 2
2 Swedish summary / Svensk sammanfattning ................................................................................ 3
3 Background .................................................................................................................................. 3
3.1 Malaria .................................................................................................................................. 3
3.2 Artemisinin ............................................................................................................................ 4
3.3 Emerging resistance............................................................................................................... 5
3.4 How to find resistance ........................................................................................................... 6
3.5 Genetic markers for resistance ............................................................................................... 7
3.5.1 PfMDR1 and PfCRT ....................................................................................................... 7
3.5.2 Cambodian news ............................................................................................................ 9
3.6 Igombe ................................................................................................................................ 10
4 Methods ..................................................................................................................................... 11
4.1 Study area and design .......................................................................................................... 11
4.2 Recruitment of patients ........................................................................................................ 11
4.3 Ethics approval .................................................................................................................... 11
4.4 Treatment of patients and follow-up .................................................................................... 11
4.5 Molecular analysis ............................................................................................................... 12
4.5.1 DNA extraction ............................................................................................................. 12
4.5.2 DNA amplification and gel electrophoresis ................................................................... 12
4.5.3 DNA sequencing ........................................................................................................... 13
5 Results ....................................................................................................................................... 13
6 Discussion .................................................................................................................................. 16
References .................................................................................................................................... 19
Appendix ........................................................................................................................................ 1
2
Acknowledgements
I would like to express my special appreciation and thanks to my supervisor Dr. Göte Swedberg.
Thank you so much for arranging this opportunity for me to go to Tanzania and for always being
patient answering questions and helping out in the laboratory. Thank you also to my two local
supervisors in Mwanza Erasmus Kamugisha and Karol Maro. You not only assisted me in my
studies and work there but you also helped me to create a home in your wonderful country. Finally I
would like to express my love and gratefulness to my two friends and fellow students joining me to
Mwanza; Maria Sjögren and Emelie Lund. Thank you for an amazing trip and a wonderful
adventure!
1 Abstract
The development of Plasmodium falciparum parasites resistant to artemisinin (ART), so far only
reported present in south-east Asia, poses a big threat towards the malaria affected part of the world.
Since we do not yet know how artemisinins work or exactly what constitutes ART resistance, an
exact way to monitor its spread is difficult. Some genes have been proposed as molecular markers
for a decreased ART suspectibility when containing certain polymorphisms. Among these are the
genes coding for P. falciparum chloroquine resistance transporter (PfCRT), P. falciparum
multidrug resistance 1 (PfMDR1) and now most recently the gene located on chromosome 13 that
coding for the K13 kelch protein, also known as the ‘K13 propeller’. In this study data from 38
malaria patients in Igombe, Tanzania, treated with artemisinin-lumefanterine (AL) combination
therapy, was used to determine the efficacy of AL treatment. Also, for the first time in this area, the
prevalence of variation inside the K13 domain in the malaria parasites was quantified. Patients’
clinical status and parasite blood levels were followed up for three days and blood samples were
collected for DNA sequencing. Results proved AL has a high efficacy in the area, curing all patients
within three days. Furthermore, one out of 34 patients carried a possible polymorphism in its K13
nucleotide sequence. The results are consistent with the clinical situation in Tanzania, where ART
combination therapy today has a good effect and resistance is not present, however, it is not possible
to say if this polymorphism is linked to ART resistance. Further studies are needed to find reliable
molecular markers to monitor ART resistance globally.
3
2 Swedish summary / Svensk sammanfattning
Plasmodium falciparum är den dödligaste av de olika parasitarterna som orsakar malaria.
Utvecklingen av falciparumstammar resistenta mot ett av de mest använda malarialäkemedlen,
artemisinin (ART), utgör ett stort hot mot den malariadrabbade delen av vår värld. Hittills har dessa
bara rapporterats funna i sydöstra Asien. Ett sätt att övervaka förekomst och spridning av resistens
är att finna små förändringar i parasiters genom, genetiska polymorfismer, som kan kopplas till en
försämrad läkemedelskänslighet. Några möjliga sådana polymorfismer har redan föreslagits för
artemisininresistens i gener så som de som kodar för P. falciparum chloroquine resistance
transporter (PfCRT), P. falciparum multidrug resistance 1 (PfMDR1) och nu nyligen den genen
belägen på kromosom 13 som kodar för det så kallade K13-kelchproteinet. I denna studie utförd i
Igombe, Tanzania, har 38 malariapatienter som erhållit behandling med artemisinin-lumefanterine
(AL), följts för att undersöka behandlingens effektivitet samt förekomsten av polymorfismer i K13-
domänen i parasiternas genom. Patienternas kliniska tillstånd samt parasitnivåer i blodet har följts
upp i tre dagar och blodprover har tagits för gensekvensering. Resultaten visar att AL har fortsatt
hög effektivitet i området samt att en av 34 patienter bar på en parasitstam med en möjlig
polymorfism i K13 domänen. Då förändringar i K13-domänen hittills bara kopplats till
artemisininresistens i Asien, kan man inte dra några vidare slutsatser av dessa resultat. Vidare
studier bör göras för att finna en pålitlig och globalt användbar genmarkör för ART-resistens för att
kunna följa dess utveckling.
3 Background
3.1 Malaria
Although increased prevention and control measures have reduced the malaria mortality rate in the
recent decades, it still remains the most important parasite disease worldwide. Among the five
species of malaria parasites that infect human, Plasmodium falciparum is the one causing practically
all deaths. In 2012 about 3.4 billion people lived in malaria endemic areas. The same year there
were about 207 million malaria cases and the number of deaths it caused was estimated to be 627
000. Among the deaths, around 90 % occurred in Sub-Saharan Africa and most of them were among
children under the age of five years [1]. A falciparum infection has a good prognosis if diagnosed at
4
an early stage and when effective chemotherapy is administered, but left untreated its mortality rate
is high. Today the World Health Organization (WHO) recommends artemisinin combination therapy
(ACT) as the first-line treatment for uncomplicated malaria caused by Plasmodium falciparum.
3.2 Artemisinin
Artemisinin (ART) was discovered by Chinese scientists during the Vietnam War in 1971 when a
new treatment for chloroquine resistant malaria was badly needed [2]. Thereafter, many potent
derivates have been produced including arthemeter (ATM), artesunate and artemotil. Despite being
in use ever since, nobody has been able to determine their mechanism of action. The different
models proposed, as well as evidence both supporting and opposing them, have been summarized in
a review article by Ding and colleagues include interference with the heme-detoxification pathway;
induction of alkylation of translationally controlled tumor protein; inhibition of the
sarco/endoplasmatic reticulum membrane calcium transporting ATPase 6; and interference with
mitochondrial function [3].
ART compounds have broad stage specificity and compared to other anti-malarials, a more effective
elimination of the young asexual circulating ring stage parasites, inhibiting these from further
maturation and sequestration (the adherence of infected erythrocytes containing late developmental
stages of the parasite to the endothelium of capillaries and venules). This, while also killing the
mature blood-stage parasites. Altogether, this makes their total parasite elimination extremely fast,
achieving a 10 000-fold reduction in parasite number per asexual cycle [4]. Most patients have
cleared their peripheral parasitemia by day 3 (~72 h) after the start of the treatment [5].
Given in monotherapy, ART demands at least six-seven days therapy duration to act as curative.
Since in practice it is often used shorter than this, recrudescence (the reappearance of parasites that
have escaped treatment) and reinfection is common. ART derivatives have therefore been combined
with longer lasting partner drugs, which include lumefantrine (in combination with ATM globally
the most widely used ACT), amodiaquine, mefloquine, sulfadoxine–pyrimethamine, piperaquine
and pyronaridine.
5
3.3 Emerging resistance
The first proof of parasite ART resistance was reported from western Cambodia in 2008 [6]. In a
study conducted there between 2006 and 2007, four out of 60 patients treated with artesunate during
seven days had parasites reemerging within 28 days after start of the treatment (a criterium of
resistance). Two of them had prolonged parasite-clearance time (135 and 95 hours compared to
median of 52.2 h among the other cured patients) in spite of adequate plasma drug concentrations.
In vitro test analyzing dihydroartemisinin (the active metabolite of all ART compounds)
susceptibility also showed a half-maximum inhibitor concentration (IC50) notably higher than
normal within these subjects.
Further studies from Cambodia and Thailand have added evidence supporting emerging ART
resistance by showing prolonged clearance rates. Between 2007 and 2008, parasite clearance rates
from 40 patients from either site were compared [7]. Cambodian patients treated with artesunate at a
dose of 4 mg/kg had a median parasite clearance time of 84 hours compared to 48 hours in
Thailand. However, the parasites showing a slow clearance rate did not show any increased
susceptibility in conventional in vitro resistance testing, nor was there any correlation with
previously studied drug resistance genetic markers. The clinical effectiveness of oral ACT was
confirmed since cure rates remained around 95%. Also, after observing malaria patients treated with
various ACT's between the years 2001-2010, an increase in parasite clearance half-life was found in
Thailand (2.6 h to 3.7 h) while steadily high mean dito (5.5 h) was seen in Cambodia [8]. The
proportion of variation in parasite clearance attributed to parasite genetics also increased from 30%
to 66%. A larger longitudinal study from the northwest border of Thailand summarized artesunate-
mefloquine treatment in 3264 malaria cases between the years 1995-2007. It showed a similar result
with remaining high clinical efficacy, but slowly increasing parasite clearance times which also
increased the risk of gametocytemia [9]. Finally, ART resistant falciparum malaria has been
reported from southern Burma [10].
When chloroquine resistance emerged in the same area in Asia in the 50's and 60's and then reached
Africa in the early 80’s, it caused millions of deaths [11]. Evidence has been proposed that
resistance to sulfadoxine- pyrimethamine, the next drug of choice after chloroquine resistance had
emerged, also arrived to Africa from south-east Asia [12]. Should ART resistance develop in Asia, it
is likely to once again spread to Africa where its consequences surely would be devastating.
6
3.4 How to find resistance
Because ACTs have the ability to quickly reduce the patient's clinical symptoms associated with
parasitemia, many patients stop taking them as soon as they feel better. This opens up for treatment
failure. Monotherapy with artemisinins are associated with a high rate of recrudescences, however
this is not the same thing as resistance and it is not necessarily caused by it. It is also hard to
distinguish recrudescence from reinfection if polymerase chain reaction (PCR) is not used. By PCR
it is possible to sequence the parasites’ DNA and differing one primarily infecting clone from
another reinfecting one. Only treatment failure is therefore no sign of ART resistance since this can
be a result of incomplete duration of treatment, variations in population immunity and metabolism
(i.e. spleen function), variations in drug quality and reinfection. And finally, since the ART is used
in combination with a partner drug, resistance patterns are even more complex. Due to lack of
available in vitro methods or good molecular markers, WHO has defined artemisinin resistance
upon clinical and parasitological outcomes observed during routine therapeutic efficacy studies of
ACTs and clinical trials of artesunate monotherapy. The definition can be viewed in Table 1.
Artemisinin resistance:
• an increase in parasite clearance time, as evidenced by ≥ 10% of cases with parasites detectable on
day 3 after treatment with an ACT (suspected resistance)
or
• treatment failure after treatment with an oral artemisinin-based monotherapy with
adequate antimalarial blood concentration, as evidenced by the persistence of
parasites for 7 days, or the presence of parasites at day 3 and recrudescence within
28 days (confirmed resistance) [13].
Table 1. WHO definition of artemisinin resistance.
Parasite clearance time (the time between the start of administration of anti-malarial treatment until
parasites are no longer detectable in the peripheral blood film) is the most robust and used method
to measure therapy response but it is not precise and affected by several factors besides drug
susceptibility [14]. Comparing parasite clearance data from over 18 000 patients suffering from
falciparum malaria in 25 different countries, the factors associated with a prolonged clearance rate
in vivo were be established [5]. The most prominent were high parasite density on admission, low
level of malaria transmission in the area and a less effective partner-drug to the ART compound in
7
the ACT. The study confirmed that ART resistance is highly unlikely if the proportion of patients
who have a positive smear result on day 3 is <3% (with pre-treatment parasite densities of <100,000
parasites/mL, given the currently recommended 3-day ACT). Therefor the day 3 blood slide was
proposed as a measurement for detecting decreased susceptibility in vivo.
To analyze the heritability in parasite clearance half-life - that is the proportion of variance in a trait
that is explained by genetics - trait variation can be compared between parasites that are identical
across the genome but have infected different patients. The blood samples and clearance data from
efficacy trials of ART based therapy in western Cambodia in 2007–2008 were analyzed in such a
way. Results linked a substantial proportion (56%–58%) of the variation in clearance rate to parasite
genetics which could be seen as proof of slowing clearance rate being a parasite trait [15].
3.5 Genetic markers for resistance
3.5.1 PfMDR1 and PfCRT
Many studies have performed genotyping of single nucleotide polymorphisms (SNPs) to see if there
is any special signature SNP pattern that is positively selected for by, or associated with, a slower
parasite clearing rate. A SNP is a DNA sequence variation occurring when a single nucleotide - A,
T, C or G - in the genome differs between members of a biological species or between paired
chromosomes. Identification of the genetic basis of resistance would provide tools for molecular
surveillance, facilitating efforts to contain a developing resistance. Several genes have been
associated with alterations in parasite in vitro susceptibility to artemisinins. Among these are the
genes encoding for the P. falciparum chloroquine resistance transporter (PfCRT) and the P.
falciparum multidrug resistance 1 (PfMDR1) transporter. These are transporter proteins in the
digestive vacuole membrane, a specialized proteolytic organelle wherein hemoglobin is degraded
and detoxified to produce aminoacids used for parasite growth and maturation.
Mutations in PfCRT have been shown to confer chloroquine resistance [16]. The gene differs
widely between different geographical regions but all mutant haplotypes share the same PfCRT
mutations K76T and A220S suggesting these are the ones most important for chloroquine resistance
[17]. Studies show that alterations in PfCRT can also be associated with changes in susceptibility to
other antimalarials including quinine, monodesethylamodiaquine (the primary metabolite of
amodiaquine), halofantrine, lumafentrine and finally ART [16]. Various PfCRT mutant alleles
introduced by allelic exchange in parasite clones and associated with chloroquine resistance induced
8
an increased (ca 2.5-4-fold) sensitivity to ART and dehydroartemisinin in vitro [17]. Additionally,
other PfCRT polymorphisms have showed a 2-fold decrease in ART sensitivity [18].
Mutations within the gene encoding PfMDR1, also known as P-glycoprotein homologue-1, have
been shown to confer chloroquine resistance, whereas the mutation alone is not enough to produce
such resistance. This suggests that the mutation might help to modulate and enhance chloroquine
resistance alternatively compensate for physiological changes due to PfCRT mutations [19-20].
How different PfMDR1 polymorphisms and mutations have been seen to influence on artesunate,
ART and dehydroartemisinin susceptibility in vitro is summarized in a review by Ding et al [3].
Some polymorphisms such as the N86Y and the Y184F are associated with slightly increased
sensitivity to the three compounds. Others, such as the S1034C and N1042D were associated with
an either increased or decreased dito. There are also several in vitro studies indicating that an
increased gene copy number of PfMDR1 may significantly decrease parasite susceptibility to ARTs
and vice versa that a decreased gene copy number can increase artemisinin susceptibility.
Artemether-lumefanterine (AL) is known to induce expression of several SNPs; most prevalent are
PfMDR1 N86, 184F and D1246 and the PfCRT K76 alleles [21-23]. Results also indicate that usage
of AL can increase prevalence of wild type genotypes of the PfCRT and PfMDR1 genes wherein
mutations are associated with chloroquine resistance.
Retrospective studies from Malawi, the first country in Africa where chloroquine was replaced by
other first-line treatments due to increasing treatment failure, aimed to determine whether
withdrawal of chloroquine could lead to reemergence of chloroquine sensitivity [24]. The
prevalence of the PfCRT 76T molecular marker for chloroquine-resistant Plasmodium falciparum
malaria was measured. Results showed a prominent decrease in prevalence of the chloroquine-
resistant PfCRT genotype from 85% in 1992 to 13% in 2000. Further studies aiming to trace these
parasites showed that they likely represent a reexpansion of the susceptible parasites that survived
in the population despite widespread drug pressure in the region [25]. The resurgence of susceptible
parasites is best explained by a fitness cost of drug resistance that allows surviving susceptible
organisms to outcompete resistant organisms in the absence of drug pressure. For example, signs of
lesser virulence, in this case the inability to cause a symptomatic infection with fever, have been
observed among the PfCRT and PfMDR1 mutant parasites compared to their wild-type relatives
[26].
9
Similar studies performed in the Democratic Republic of Congo, Kenya and Tanzania, where
chloroquine was withdrawn and replaced with ACTs in 2002, 1998 and 2001 respectively, also
show a decline in the prevalence of the chloroquine resistance PfCRT and PfMDR mutants and a
return of wild-type/sensitive strains [27-29; 23].
3.5.2 Cambodian news
Recent clinical trials of artesunate efficacy conducted by Takala-Harrison et al. in Cambodia
examined genotypes for signatures of positive selection and association with parasite clearance
profiles, and both parasite clearance half-life and clearance time following artesunate treatment
were found to be heritable. 8079 SNPs were examined through genome-wide association and four
of these, one on chromosome 10 (MAL10-688956), two on 13 (MAL13-1718319 and MAL13-
1719976) and one on 14, were significantly associated with delayed parasite clearance [30].
Interestingly all the three SNPs on chromosomes 10 and 13 lie in or near genes involved in the same
DNA damage-tolerance pathway used for postreplication repair.
Also using genome-wide association, Cheeseman and colleagues [31] examined SNP patterns in
parasites in Cambodia, Thailand and Laos to determine which ones were under strong positive
selection. Also here, a region on chromosome 13 showed a strong positive selection as well as an
evident association with prolonged parasite clearing rates.
Ariey et al. [32] applied an alternative method to study molecular markers. Here ART sensitive
parasite clones were in vitro exposed to ART intermittently during five years. Then genome
sequencing was used to compare the surviving parasites clones with parasites from clinical trials in
Cambodia showing clinically varying ART susceptibility. The study, published in January 2014,
showed one gene was found to strongly correlate with in vitro resistance, clinically prolonged
clearance rates and the spread of decreased susceptibility among parasites in different Cambodian
provinces. The gene, PF3D7_1343700 kelch propeller domain (‘K13-propeller’), is located within
one of the SNP regions on chromosome 13 mentioned by Takala-Harrison and close to the region
under positive selection mentioned by Cheeseman, and it encodes a kelch protein called K13. Kelch
proteins are a widespread group of proteins involved in a variety of protein–protein interactions,
and the normal function of K13 is not yet known. However this polymorphism could serve as a
useful molecular marker for tracking the emergence and spread of ART resistant P. falciparum.
10
3.6 Igombe
Tanzania introduced AL as first-line treatment country-wide in the last quarter of 2006, replacing
sulfadoxine-pyrimethamine (SP) that had been equally introduced in 2001 as first-line treatment due
to the increased chloroquine resistance [33-34]. Studies of AL treatment efficacy in uncomplicated
falciparum malaria in East Africa so far only show good result with high curing rates and few
treatment failures [35-36]. However evidence of a continuous selection of molecular markers
associated with artemether-lumefantrine tolerance/resistance within the parasites has been seen. In a
study analyzing dried blood spots collected during six consecutive studies from children with
uncomplicated falciparum malaria in the Bagamoyo District, Tanzania, showed a statistically
significant yearly increase of polymorphisms in PfMDR1 N86, 184F, D1246 and PfCRT K76
between 2006–2011 from 14% to 61%, 14% to 35%, 54% to 85% and 49% to 85% respectively
[37].
This study, performed in Igombe in northern Tanzania, aims to establish the efficacy of artemisinin-
lumefanterine treatment as well as the prevalence of drug resistance markers within falciparum
parasites causing uncomplicated malaria infection. A similar study was performed in the same area
by E. Kamugisha et al. between 2010 and 2011 [38]. 103 patients were followed up for 28 days. The
AL efficacy proved high with a mean parasite clearance rate at 34.7 h. When examining drug
resistance molecular markers, prevalence of parasites carrying wild type alleles in PfCRT 76 K and
PfMDR1 86N was high compared to other studies previously done in Tanzania which might
indicate return of chloroquine sensitive parasites either due to proper control of chloroquine or
selection of wild type due to AL treatment. It also showed a high frequency of mutations in PfCRT
and PfMDR1 among the reinfections and a pattern in molecular markers indicating sulfadoxine-
pyrimmethamine resistance. In this study however, we will focus on the K13 domain to see if it is
variable or not in the area. Much variability in the gene could possibly indicate a developing drug
resistance. It is part of a larger study planned by Erasmus Kamugisha at Weill-Bugando University
College of Health Sciences, Mwanza, concerning the efficacy of artemisinin and the prevalence of
molecular markers associated with ART resistance.
11
4 Methods
4.1 Study area and design
This study was an interventional prospective single cohort study. Patients were recruited from the
health center of Igombe, a semi-urban area with a population of around 40 000 inhabitants near the
city of Mwanza, Tanzania. Here, malaria is mesoendemic, that is, transmission is seasonal under
normal rainfall conditions but in times of drought, it will decline. Rain periods in northern Tanzania
occur in October to December and in March to May.
4.2 Recruitment of patients
Patients attending the health clinic between November 2013 and January 2014 with incidence of
fever ≥ 37.5 °C or a history of fever during the previous 48 h were screened for falciparum
infections with a Paracheck ® Rapid Test for P. falciparum malaria (MRDT). If this was positive,
thin and thick blood films were obtained for P. falciparum parasite count and classification and
blood samples were collected for further DNA analysis. Patient data and exclusion criteria can be
viewed in the Appendix.
4.3 Ethics approval
Ethical approval to conduct the research was obtained from the joint CUHAS/Bugando ethics
committee and regional administration of Mwanza. All patients gave an informed consent before
being enrolled in this study. In case the patient was a minor, consent was obtained from the parent
or guardian of the child.
4.4 Treatment of patients and follow-up
Standard treatment of the admitted patients was a six-dose regimen of artemether-lumefanterine
(Coartem ®, Novartis), each tablet containing 20 mg of artemether and 120 mg of lumefanterine.
Tablets were administered twice daily during three days. A first dose was given as a direct observed
therapy, after which the patient was kept and observed for 30 minutes. Then the remaining therapy
was given to the patient to take eight hours after the first dose and then morning and evening the
12
two following days. Children weighing from 5-14.9 kg received one tablet, those from 15-24.9 kg
two tablets, those from 25-34.9 kg three tablets and finally those above 35 kg four tablets. Tablets
were crushed in water for young children unable to swallow whole tablets. If a patient vomited
within 30 minutes after the first dose, a new one was administered and if repeatedly vomiting, the
patient was excluded from the study. Patients with fever were administered paracetamol.
Repeated evaluations were performed on scheduled occasions day one, two and three or in case the
patient did not feel well. At these occasions blood samples were collected on filter paper and body
temperature was measured. Also, an MRDT was taken and if this was positive, the blood was
examined in microscope for parasite counting.
4.5 Molecular analysis
All the molecular analysis was performed at the Department of Medical Biochemistry and
Microbiology at Uppsala University.
4.5.1 DNA extraction
DNA was extracted from the filter papers using Tris-EDTA (TE) buffer-based extraction. For this
purpose, only the day 1 sample was used. The Tris-EDTA buffer was composed of 10 mM Tris, pH
8.0 (Tris base plus Tris-HCl) and 0.1 mM EDTA in distilled water. A piece of filter paper 3.0 mm in
diameter was cut out and placed into a tube, and then 65 µL of TE buffer was added to each tube
and left to soak at room temperature for 1 hour. The tubes were then incubated at 50 °C for 15
minutes followed by another 15 minutes at 95 °C. During latter incubation the punches were
pressed towards the bottom of the tube a few times with a pipette tip. The liquid extracts were then
collected to new tubes and stored at -20 °C until further use.
4.5.2 DNA amplification and gel electrophoresis
The extracted DNA was amplified with nested mutation-specific polymerase chain reaction (PCR).
The following ingredients were added to a PCR tube: 2 µL of Thermo Scientific 10x Dream Taq
Green buffer, 2 µL of 1.0 mM KAPA dNTP Mix, 0.25 µL of 5 U/µL Thermo Scientific Dream Taq
DNA Polymerase, 1 µL of the forward primer and 1 µL of the reverse primer and then finally 2 µL
of parasite DNA.
The forward and reverse primer used in the first outer PCR reaction was Eurofins MWG Operon
13
K13-1 5'-CGG AGT GAC CAA ATC TGG GA-3' and Eurofins MWG Operon K13-4 5'-GGG AAT
CTG GTG GTA ACA GC-3 respectively'. Forward primer in the second nested PCR reaction was
Eurofins MWG Operon K13-2 5'-GCC AAG CTG CCA TTC ATT TG-3' AND P2 and reverse
primer was Eurofins MWG Operon K13-3 5'-GCC TTG TTG AAA GAA GCA GA-3'. The PCR
program used was the same in both of the PCR reactions and consisted of 94 °C 2 min; 30 cycles:
94 °C 30 sec, 60 °C 30 sec, 72 °C 1 min 30 sec; 72 °C 5 min; 4 °C hold.
5 µL of finished products from the nested PCR was used in agarose gel electrophoresis to conferm
whether the PCR was successful or not. The gel was prepared of 1 g SeaKem LE Agarose put into
100 ml of 1xTBE buffer and stored at 46 °C. Before letting the gel turn hard, about 1.5 µL of 0.625
mg/mL ethidium bromide was added to 50 mL gel.
4.5.3 DNA sequencing
After electrophoresis the PCR product was prepared to be sent for DNA sequencing. First 7.5 µL of
ExoSAP was added to 15 µL of PCR product to enzymatically clean up the PCR products of
unincorporated primers and dNTPs. Then the samples were incubated at 37 °C for 30 minutes and
at 95 °C for five minutes. 2 µL of the solution was mixed with 0.4 µL of primer (the forward primer
previously used for the internal PCR were used for sequencing) and finally distilled water was
added to each sample so that it consisted of 18 µL in total. Sequencing was done using the Sanger
method. The obtained nucleotide sequences were viewed in the program 4Peaks and compared with
database sequences of the 3D7 strain from Asia using the BLAST program. Samples that were
unreadable or varied from the 3D7 strain were again sent to DNA sequencing but this time they
were prepared with the reverse primer from the previous internal PCR.
5 Results
Out of all the patients coming to the health station between the 13th November and the 14th of
January, 38 patients proved suitable for and consented to being a part of the study. They all had an
age between 6 months and 30 years and 58 % were female. Mean parasite blood concentration at
admission was 31 670 parasites / µL. Nine patients had parasites in the day two parasite blood count
(mean concentration among these was 8570 p / µL) but they were all negative in the day three
parasite blood count, and likewise, none of the patients from which body temperature was measured
14
had fever on day three. Four of the patients did not show up for day two and three analysis.
However, since the study on K13 prevalence was done with only the day one blood samples, they
could still be part of the study.
After DNA extraction and amplification, 34 out of the 38 samples proved to contain the K13 gene
judging by the gel electrophoresis results. A new PCR round was performed with the samples that
did not contain the gene, but as they showed no different results, they were excluded from the study.
In the first DNA sequencing round 17 samples did not show any variation in their nucleotide
sequence compared to the 3D7 strain, 15 showed variation in one or more positions and finally the
last two were not readable. The once showing variation and the ones unreadable, altogether 17
samples, were prepared again for sequencing with the reverse primer. Out of these, 15 did not show
any variation, one was again not readable and one showed variation in the same nucleotide position
as in the first sequencing run.
Figure 2.
Results of the laboratory analysis.
Picture 1.
Agarose gel of the
obtained PCR
products. No 3, 6, 29 and 31 do not show
any band
representing
presence of the K13
gene.
15
The one sample showing a suspected polymorphism (origin from patient number 8) had a cytocine
instead of a guanine when comparing to the normal nucleotide sequence. This nucleotide is one of
three encoding the amino acid in position 616, and such a mutation as mentioned above would alter
the translated amino acid from a proline to a serine.
The mutation did not match any of the previously reported polymorphic codons from Asia [32].
When compared to registers of polymorphisms from Africa, no match was found either [39].
Picture 3. Illustration of the polymorphism in sample number 8 using the program 4Peaks. Polymorphisms
can be visualized by two peeks present at the same position. To the left is a picture of the forward strand
and to the right is a picture of the reverse strand.
Picture 2. Illustration from the study performed by Ariey et al. [32] showing a segment of the P. falciparum K13 gene. In
the black boxes are polymorphisms found in their study. In the red box is the suspected polymorphism found in our present study in nucleotide position number 1844 affecting the amino acid in position number 616.
16
6 Discussion
In this study, 38 patients were treated with ACT for uncomplicated P. falciparum malaria infection.
All were MDRT negative at the third day of treatment. When analyzing a segment of the K13 gene
of the infecting parasites, one out of 34 showed a possible polymorphism in its nucleotide sequence.
It is visible that ACT in this area has a good effect, curing all patients within three days. It is
however not possible to determine the prevalence of recrudescence or reinfection since the patients
were not followed up for long enough.
The choice to study the K13 propeller was made since it only required the day 1 sample to establish
its baseline prevalence before the start of ACT treatment. A longer follow-up of the patients was
planned for at the beginning of the study; however it proved complicated logistically and time-wise.
Also, the study provided by Ariey was rare in its ability to connect a molecular marker to both a
clinically and in vitro decreased ART susceptibility. Many studies only succeed in associating a
certain polymorphism to clinical results but when then trying it out in vitro, the association is lost.
Certainly, the fact that many genes may interact in creating resistance may play a role there. To date,
Tanzania does not have a problem with ART resistance, nor did the patients in this study show any
signs of infection with parasites with decreased drug susceptibility since they all had their blood
cleared of parasites at day 3. The patient carrying mutated parasites did not show any clinical
anomalies i.e. prolonged clearance time or deviating body temperature. The suspected outcome of
the K13 gene sequencing would therefore be expected to show very small or no nucleotide
variability. The results in this study are coherent with that. Would the prevalence of ART resistance
in the an area be high, one would also expect more numerous polymorphisms.
The sample showing variation did not match any of the previously reported polymorphisms.
However, when comparing to Asian and even African samples one must consider that
polymorphisms may vary much in between different geographical regions. Also, when comparing to
African samples, even if the polymorphism would have matched any of the previously reported
polymorphisms, it would not necessarily have meant anything since these polymorphisms have not
yet been linked to ART resistance as they have in Cambodia via comparison to clinical therapy
outcomes. Some genomic regions are naturally prone to mutation which then might or might not be
17
linked to drug resistance. Should the polymorphism be real it is therefore hard to say what
significance it has. For the protein synthesis it has the effect that it would alter a translated amino
acid from a proline into a serine in the amino acid position 616, thus affect the final K13 protein
structure. We do not know if this could alter the function of the protein, nor yet at all what the role
of this protein is. Assuming the polymorphism is real, the conclusion one can draw is that the
mutation reported from Asia is not present in this part of Tanzania and that the method used in this
study can be used to continuously follow up the development of the prevalence of the K13 propeller
gene.
There was a big difference in the results from the first DNA round to the second one, where 15
samples were positive for possible polymorphisms at first whereas only one of them was so later on.
It is hard to say exactly what lay behind these results, but probably there was a technical problem in
the first round. First, what could have been wrong is the relationship between the availability of
primers and PCR product in the sample sent for DNA sequencing. Secondly, there could have been
something wrong with the primers used making them bind improperly to the PCR product
alternatively something wrong with the PCR product making it a bad match for the primers. The
latter is not believable here since apparently the reverse primer seemed to bind well to the DNA.
Third, it is not ideal to use the same primers for the PCR and the DNA sequencing since by-
products not visible in the agarose gel are regularly created in the PCR which can disturb the results
further along. It is hard to say how many times molecular analysis like these shall be repeated to be
able to draw reliable conclusions of the results, but in bigger studies repetition is often performed
no matter what the results look like. What one can say is that in this study when achieving the
results from the first sequencing round, the whole process from the PCR and on should have been
repeated. What made the final polymorphism likelier to be true than the previous once was that the
surrounding ‘background peaks’ were much smaller in their amplitude, and the aberrant peak was of
a high amplitude. This pattern signifies that there is more than one clone present in the sample.
If more time had been assigned to collecting data for this project, a larger number of patients would
have been followed up for a longer period of time with follow-ups scheduled for day 7, 14 and 28 as
well. Then, recrudenscent parasites as well as parasites with somewhat prolonged clearing rates
would have been particularly interesting to analyze to see if they possessed any alterations in the
K13 gene. Reinfection rates could also have been interesting to investigate if more data had been
collected, however if found common, this would rather have been an indication of a decreasing
susceptibility towards lumefanterine than towards artemisinin. Lumefanterine, being the drug that
18
stays in the body for a longer time, protects against reinfection as long as it stays in a concentration
high enough to be inhibitory for parasite growth. If more time would have been assigned for lab
analysis, it would have been interesting to do analyses of the PfMDR1 and PfCRT
mutation/wildtype prevalence to compare these with the previous studies made by Erasmus et al. An
increase in wild type prevalence would strengthen the theory that a chloroquine withdrawal and an
artemisinin-lumefanterine usage decrease the prevalence of chloroquine resistance molecule
markers in favor of return of wild type alleles.
It is important to continue the search for molecular markers for ART resistance to be able to monitor
its spread and if possible contain it. The three day resistance-definition is a subject to potential
confounding factors such as spleen function, hemoglobin abnormalities and reduced immunity,
which all can delay parasite clearance. Also the recrudescence part of the WHO definition is not
waterproof. As mentioned before it is hard to separate recrudescence from a reinfection. Even when
using PCR, one cannot be certain that a seemingly new clone of falciparum which makes a patient
fall ill again has not been present in the blood since the primary infection. A patient can be infected
by several clones at once. Blood samples for analysis are taken from the peripheral blood of a
patient and all parasites are sometimes not present in the peripheral blood at once. Therefore, it is
possible to miss a primarily infecting parasite clone. This clone could later be a source of
recrudescence and when comparing it to the original parasites with PCR and finding it different, one
would probably judge it to be a reinfection rather than a recrudescence.
The WHO definition of ART resistance will certainly adapt over time when established molecular
markers or better in vitro methods are available. Finally, understanding the gene, or probably the
several genes, underlying artemisinin resistance would help us understand not only the mechanism
of this resistance but also the mechanism of artemisinin itself.
19
References
1. World Health Organization & Global Ma-
laria Programme. World malaria report
2012. (World Health Organization, 2012)
2. Miller, L. H. & Su, X. Artemisinin: Dis-
covery from the Chinese Herbal Garden.
Cell 146, 855–858 (2011).
3. Ding, X. C., Beck, H.-P. & Raso, G.
Plasmodium sensitivity to artemisinins:
magic bullets hit elusive targets. Trends
in Parasitology 27, 73–81 (2011).
4. White, N. Antimalarial drug resistance
and combination chemotherapy. Philo-
sophical Transactions of the Royal Socie-
ty B: Biological Sciences 354, 739–749
(1999).
5. Stepniewska, K. et al. In Vivo Parasito-
logical Measures of Artemisinin Suscep-
tibility. The Journal of Infectious Diseas-
es 201, 570–579 (2010).
6. Noedl H, Se Y, Schaecher K, Smith BL,
Socheat D, Fukuda MM. Evidence of ar-
temisinin-resistant malaria in Western
Cambodia. N Engl J Med 2008;
359:2619-2620.
7. Dondorp, A. M. et al. Artemisinin re-
sistance in Plasmodium falciparum ma-
laria. New England Journal of Medicine
361, 455–467 (2009).
8. Phyo, A. P. et al. Emergence of artemis-inin-resistant malaria on the western
border of Thailand: a longitudinal study.
The Lancet 379, 1960–1966 (2012).
9. Carrara, V. I. et al. Changes in the Treat-
ment Responses to Artesunate-
Mefloquine on the Northwestern Border
of Thailand during 13 Years of Continu-
ous Deployment. PLoS ONE 4, e4551
(2009).
10. Kyaw, M. P. et al. Reduced Susceptibility
of Plasmodium falciparum to Artesunate
in Southern Myanmar. PLoS ONE 8,
e57689 (2013).
11. T Mita, K Tanabe. Evolution of Plasmo-
dium falciparum drug resistance: implica-
tions for the development and contain-
ment of artemisinin resistance. Japanese
Journal of Infectious Diseases 65, 465-
475 (2012)
12. Roper, C. et al. Intercontinental spread of
pyrimethamine-resistant malaria. Science
305, 1124–1124 (2004).
13. World Health Organization & Global Ma-
laria Programme. Update on artemisinin
resistance – April 2012. (World Health
Organization, 2012).
14. White, N. J. The parasite clearance curve.
Malaria journal 10, 278 (2011).
15. Anderson, T. J. C. et al. High Heritability
of Malaria Parasite Clearance Rate Indi-cates a Genetic Basis for Artemisinin Re-
sistance in Western Cambodia. The
Journal of Infectious Diseases 201, 1326–
1330 (2010).
16. Sidhu, A. B. S. Chloroquine Resistance in
Plasmodium falciparum Malaria Parasites
Conferred by pfcrt Mutations. Science
298, 210–213 (2002).
17. Cooper, R. A. et al. Alternative mutations
at position 76 of the vacuolar transmem-
brane protein PfCRT are associated with
chloroquine resistance and unique stereo-specific quinine and quinidine responses
inPlasmodium falciparum. Molecular
pharmacology 61, 35–42 (2002).
18. Valderramos, S. G. et al. Identification of
a Mutant PfCRT-Mediated Chloroquine
Tolerance Phenotype in Plasmodium fal-
ciparum. PLoS Pathogens 6, e1000887
(2010).
19. Reed, M. B., Saliba, K. J., Caruana, S. R.,
Kirk, K. & Cowman, A. F. Pgh1 modu-
lates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum.
Nature 403, 906–909 (2000).
20. Wellems, T. E. & Plowe, C. V. Chloro-
quine-resistant malaria. Journal of Infec-
tious Diseases 184, 770–776 (2001).
21. Sisowath, C. et al. The role of pfmdr1 in
Plasmodium falciparum tolerance to ar-
temether-lumefantrine in Africa: pfmdr1
and artemether-lumefantrine. Tropical
Medicine & International Health 12,
736–742 (2007).
22. Sisowath, C. et al. In vivo selection of Plasmodium falciparum pfmdr1 86N cod-
ing alleles by artemether-lumefantrine
(Coartem). Journal of Infectious Diseases
191, 1014–1017 (2005).
23. Sisowath, C. et al. In Vivo Selection of
Plasmodium falciparum Parasites Carry-
ingthe Chloroquine‐Susceptible pfcrt K76
Allele after Treatment with Artemether‐Lumefantrine in Africa. The Journal of
Infectious Diseases 199, 750–757 (2009). 24. Kublin, J. G. et al. Reemergence of chlo-
roquine-sensitive Plasmodium falciparum
malaria after cessation of chloroquine use
1
in Malawi. Journal of Infectious Diseases
187, 1870–1875 (2003).
25. Laufer, M. K. et al. Return of Chloro-
quine‐Susceptible Falciparum Malaria in
Malawi Was a Reexpansion of Diverse
Susceptible Parasites. The Journal of In-
fectious Diseases 202, 801–808 (2010).
26. Tukwasibwe, S. et al. Differential preva-lence of transporter polymorphisms in
symptomatic and asymptomatic falcipa-
rum malaria infections in Uganda. Jour-
nal of Infectious Diseases 2014 Jan 19.
27. Mvumbi, D. M. et al. Assessment of pfcrt
72-76 haplotypes eight years after chloro-
quine withdrawal in Kinshasa, Democrat-
ic Republic of Congo. Malaria journal
12, 459 (2013).
28. Mang’era, C. M., Mbai, F. N., Omedo, I.
A., Mireji, P. O. & Omar, S. A. Changes
in genotypes of Plasmodium falciparum human malaria parasite following with-
drawal of chloroquine in Tiwi, Kenya.
Acta Tropica 123, 202–207 (2012).
29. Eyase, F. L. et al. The Role of Pfmdr1
and Pfcrt in Changing Chloroquine,
Amodiaquine, Mefloquine and Lumefan-
trine Susceptibility in Western-Kenya P.
falciparum Samples during 2008–2011.
PLoS ONE 8, e64299 (2013).
30. Takala-Harrison, S. et al. Genetic loci as-
sociated with delayed clearance of Plas-modium falciparum following artemisinin
treatment in Southeast Asia. Proceedings
of the National Academy of Sciences 110,
240–245 (2012).
31. Cheeseman, I. H. et al. A Major Genome
Region Underlying Artemisinin Re-
sistance in Malaria. Science 336, 79–82
(2012).
32. Ariey, F. et al. A molecular marker of ar-
temisinin-resistant Plasmodium falcipa-
rum malaria. Nature 505, 50–55 (2013).
33. Mugittu, K. et al. Therapeutic efficacy of
sulfadoxine-pyrimethamine and preva-
lence of resistance markers in Tanzania
prior to revision of malaria treatment pol-
icy: Plasmodium falciparum dihydro-
folate reductase and. American Journal of
Tropical Medicine and Hygiene 71, 696–
702 (2004).
34. Ministry of Health and Social Welfare. Tanzania Malaria Programme Review
2010.
35. Agarwal, A. et al. A randomized trial of
artemether-lumefantrine and dihydroar-
temisinin-piperaquine in the treatment of
uncomplicated malaria among children in
western Kenya. Malar J 12, 254 (2013).
36. Schramm, B. et al. RESEARCH Open
Access. (2013). at
http://www.biomedcentral.com/content/p
df/1475-2875-12-251.pdf
37. Malmberg, M. et al. Temporal trends of molecular markers associated with arte-
mether-lumefantrine tolerance/resistance
in Bagamoyo district, Tanzania. Malar J
12, 103 (2013).
38. Kamugisha, E. et al. Efficacy of arteme-
ther-lumefantrine in treatment of malaria
among under-fives and prevalence of
drug resistance markers in Igombe-
Mwanza, north-western Tanzania. Malar
J 11, 58 (2012).
39. PathogenSeq - GGV: PlasmoView. at <http://pathogenseq.lshtm.ac.uk/plasmovi
ew>
40. EFFICACY, O. A. D. Assessment and
monitoring of antimalarial drug efficacy
for the treatment of uncomplicated falci-
parum malaria. (2003). at
<http://whqlibdoc.who.int/Hq/2003/WH
O_HTM_RBM_2003.50.pdf>
1
Appendix
Exclusion criteria for this study were:
presence of general danger signs according to the definitions of WHO [40];
mixed or mono-infection with other Plasmodium species detected by microscopy;
presence of severe malnutrition (defined as a child whose growth standard is below -3 z-
score, has symmetrical edema involving at least the feet or has a mid-upper arm circumference
<110 mm);
presence of febrile conditions due to other than malaria (e.g. Measles, acute respiratory tract
infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases
(e.g. cardiologic, renal and hepatic diseases, HIV/AIDS);
antimalarial treatment within previous 28 days;
regular medication, which may interfere with antimalarial pharmacokinetics including
traditional medicines;
history of hypersensitivity reactions or contraindications to any of the medicine(s) being
tested or used.
2
P
atie
nt d
ata
Patie
nt no.
Age in
Sex
Day
1 M
RD
TD
ay
1 P
ara
site
count
Day
2 M
RD
TD
ay
2 P
ara
site
count
Day
3 M
RD
T
years
(y)
& m
onth
s (
m) fem
ale
(f)
/ m
ale
(m
) p
os / n
eg
p/u
l p
os / n
eg
p/u
l p
os / n
eg
16 m
fpos
48000
pos
8800
neg
228 y
fpos
520
neg
neg
32 y
5 m
fpos
128
neg
neg
428 y
mpos
1040
neg
neg
57 m
fpos
2400
neg
neg
617 y
fpos
368
neg
neg
713 y
mpos
16000
Patie
nt did
not show
up
Patie
nt did
not show
up
87 y
mpos
480
neg
neg
92 y
mpos
128000
pos
64000
neg
10
4 y
fpos
132000
pos
2400
neg
11
1 y
10 m
fpos
40000
pos
400
neg
12
8 m
mpos
2800
neg
neg
13
11 y
fpos
16000
pos
48
neg
14
22 y
fpos
8800
neg
neg
15
5 y
mpos
120000
neg
neg
16
6 y
mpos
20000
neg
neg
17
1 y
10 m
fpos
400
neg
neg
18
19 y
fpos
24000
neg
neg
19
18 y
fpos
20000
neg
neg
20
1 y
3 m
mpos
600
neg
neg
21
5 y
fpos
80000
neg
neg
22
2 y
2 m
fpos
49000
Patie
nt did
not show
up
Patie
nt did
not show
up
23
7 m
mpos
40000
Patie
nt did
not show
up
Patie
nt did
not show
up
24
14 y
fpos
16000
Patie
nt did
not show
up
Patie
nt did
not show
up
25
2 y
fpos
4000
pos
320
neg
26
1 y
mpos
160000
neg
neg
27
7 y
fpos
12000
neg
neg
28
4 y
mpos
16000
pos
600
neg
29
12 y
fpos
400
neg
neg
30
3 y
fpos
120000
neg
neg
31
16 y
mpos
800
neg
neg
32
7 y
fpos
16000
400
neg
33
2 y
8 m
mpos
60000
160
neg
34
8 m
fpos
20000
neg
neg
35
3 y
mpos
40000
neg
neg
36
7 y
mpos
16000
neg
neg
37
3 y
mpos
1200
neg
neg
38
30 y
fpos
20000
neg
neg
3
Body temperature in case meas-
ured (°C) Patient no. Day 1 Day 2 Day 3
1 39,3 35,1
2 36,8 36,0
3 39,3 35,8 36,2
4 36,4 35,5
5
6 39,6
7 40,3
8 37,4 36,4 36,5
9 39,0 37,9 35,8
10 38,7 36,8 35,6
11 38,7 36,5 36,7
12 36,9 36,5 36,5
13 36,3 34,8 34,0
14 34,3 36,5 35,7
15 39,5 38,9 36,4
16 39,3 35,6 36,2
17 36,3 36,2 36,4
18 35,8
19 35,9 36,9 36,7
20 39,6 36,5
21 40,1 36,6
22 39,5
23 36,1
24 37,2
25 38,4
26 39,4 39,3 35,3
27 38,4 36,4
28 37,8 35,8 36,7
29 35,1 36,0 36,5
30 36,2 36,1 36,2
31 36,7 36,3 35,6
32 38,2 35,6 34,2
33 35,3 35,5 35,5
34 36,7 35,6 35,0
35 37,7 36,6
36 39,4 37,1 35,6
37 40,5 35,4
38 37,1